Non-opioid treatment; terms; preferred drug lists; discretion; drug treatment; United States Food and Drug Administration; coverage; non-opioid drugs; reimbursement; effective date.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 6 Compare versions History 16 Sponsors

No sponsors recorded.

PASSAGE PROBABILITY

24.8% Unlikely

Why this number

Stage base Passed First Chamber — base rate 45%, measured from OK's completed sessions
Momentum +2 60/100 from the pace of recorded action
Time since last action -22 560 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.